PALO ALTO, Calif., March 6, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at two investor conferences in March 2017.
- 29th Annual ROTH Conference: March 13, 2017, 9:00-9:30 am PT, at the Ritz Carlton, Laguna Niguel, Dana Point, CA;
- 27th Annual Oppenheimer Healthcare Conference: March 21, 2017, 4:30-5:00 pm ET, at the Westin New York Grand Central, New York City.
Live webcasts of both presentations will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. Replays of the webcasts will be available approximately one hour following the completion of the live events.
Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors: Andrew McDonald, LifeSci Advisors, LLC, 646-597-6987
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-the-roth-and-oppenheimer-investor-conferences-in-march-2017-300418040.html
SOURCE Eiger BioPharmaceuticals, Inc.